Any feedback?
Literature summary for 3.1.6.12 extracted from
- Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer (2013), Prostate Cancer Prostatic. Dis., 16, 277-284.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | in prostatic malignancy, activity of arylsulfatase B declines. Arylsulfatase B may be useful as a biomarker of prostate cancer. In 82% of paired cases, the biochemical recurrences show lower arylsulfatase B immunostaining at the time of prostatectomy. Arylsulfatase B immunostaining is inversely associated with Gleason scores for epithelial and stromal compartments separately and in combination. Arylsulfatase B activity is significantly less in the malignant compared to normal tissue. In association with reduced arylsulfatase B activity, total sulfated glycosaminoglycans and chondroitin-4-sulfate content are increased in the malignant prostatic tissue, and the chondroitin-4-sulfate containing matrix proteoglycan versican is also increased | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| prostate | prostate cancer | Homo sapiens | - |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
